20210401 Transgene mise a disposition ddr 2020 EN
Category: Press release
Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
20210310 Transgene TG4001 randomized Phase II EN
Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
20210310 Transgene Results 2020 EN
Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
20210302 – Transgene Scientific Conferences
Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
20210301 – Transgene BT-001 FPI – EN
First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
20210121 TG4050 1st patient HNSCC EN
Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
20210119 – ANSM Approval BT-001 EN
Transgene Appoints Gaëlle Stadtler as Director of Human Resources
20210114 Transgene – Appointment Gaelle Stadtler_EN
Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
20201221 – CTA Approval BT-001 – EN
Transgene Announces Financial Calendar for 2021
20191217 Financial calendar 2021 EN